Is Bharat Immunologica And Bio Corp a good stock to invest in?

Bharat Immunologica And Bio Corp can be analyzed on the following key metrics - TTM P/E: - Sector P/E: 34.93 Dividend Yield: 0% D/E ratio: -

Bharat Immunologica And Bio Corp Share Price

Sector: Major Drugs

Powered by

24.36 +0.98 (4.19%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 23.92

Today’s High 25.00

52 Week Low 19.00

52 Week High 35.88

Key Metrics

Market Cap (In Cr) 105.91
Beta 1.72
Div. Yield (%) 0
P/B 1.15
TTM P/E -
Peg Ratio -
Sector P/E 34.93
D/E 0.01
Open Price 23.99
Prev Close 23.38

View All Metrics

Bharat Immunologica And Bio Corp Analysis

Price Analysis

1 Week

6.81%
3 Months

6.22%
6 Month

0.26%
YTD

-1.52%
1 Year

-25.26%

Risk Meter

63% Low risk
63% Moderate risk
63% Balanced Risk
63% High risk
63% Extreme risk

Bharat Immunologica And Bio Corp News

Covaxin was developed with seed strains received from the National Institute of Virology (NIV), and the phase 3 clinical trial was co-funded by ICMR. (AFP)

Premium

India readies state-run firms to manufacture Covaxin

2 min read . 16 May 2021

View More News

Bharat Immunologica And Bio Corp Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2023

Total Revenue
44.61

Depreciation/ Amortization
0.15

Other Operating Expenses Total
8.77

Total Operating Expense
63.22

Operating Income
-18.61

Net Income Before Taxes
-22.85

Net Income
-17.06

Diluted Normalized EPS
-3.95

Period
2022

Total Revenue
78.39

Depreciation/ Amortization
0.21

Other Operating Expenses Total
9.89

Total Operating Expense
83.59

Operating Income
-5.2

Net Income Before Taxes
-9.69

Net Income
-8.75

Diluted Normalized EPS
-2.03

Period
2021

Total Revenue
85.33

Depreciation/ Amortization
0.24

Other Operating Expenses Total
10.55

Total Operating Expense
106.44

Operating Income
-21.11

Net Income Before Taxes
-24.21

Net Income
-18.11

Diluted Normalized EPS
-4.19

Period
2020

Total Revenue
66.84

Depreciation/ Amortization
0.24

Other Operating Expenses Total
9.91

Total Operating Expense
77.48

Operating Income
-10.65

Net Income Before Taxes
-14.2

Net Income
-10.21

Diluted Normalized EPS
-2.36

Period
2019

Total Revenue
83.65

Depreciation/ Amortization
0.28

Other Operating Expenses Total
12.46

Total Operating Expense
93.24

Operating Income
-9.59

Net Income Before Taxes
-7.37

Net Income
-5.79

Diluted Normalized EPS
-1.34

Period
2018

Total Revenue
34.8

Depreciation/ Amortization
0.41

Other Operating Expenses Total
5.73

Total Operating Expense
43.42

Operating Income
-8.63

Net Income Before Taxes
-7.96

Net Income
-4.26

Diluted Normalized EPS
-0.99

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Bharat Immunologica And Bio Corp Technical

Moving Average SMA

5 Day22.85
10 Day22.52
20 Day23.06

50 Day22.41
100 Day23.55
300 Day25.53

Bharat Immunologica And Bio Corp Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Pharmaids Pharmaceuticals
67.95
1.08
1.62
87.46
31.9
239.22

Welcure Drugs And Pharmaceutic
11.44
-0.27
-2.31
15.81
4.3
128.27

Bharat Immunologica And Bio Corp
24.36
0.98
4.19
35.88
19
105.91

Makers Laboratories
165.35
27.3
19.78
230
114
97.57

Ind Swift
15.12
0.4
2.72
34.49
12
81.67

Bharat Immunologica And Bio Corp Shareholding

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

16-Aug-24
General Purpose.

08-Mar-24
Others

31-Oct-23
Quarterly Results

24-Apr-23
Audited Results

09-Feb-23
Quarterly Results

17-Oct-22
Quarterly Results

11-Aug-22
Quarterly Results

30-May-22
Audited Results

08-Feb-22
Quarterly Results

29-Oct-21
Quarterly Results

Meeting Date
Announced on
Purpose

29-Dec-23
28-Nov-23
AGM

30-Sept-22
01-Sept-22
AGM

View All

Company Profile

ABOUT Bharat Immunologica And Bio Corp

Industry Major Drugs
ISIN INE994B01014
BSE Code 524663

Bharat Immunologicals and Biologicals Corporation Limited is an India-based biotechnology company. The Company is primarily engaged in the manufacture of oral polio vaccine, zinc tablet, and diarrhea management kit. It operates under various segment, namely oral polio vaccine, zinc tablets, BIB VIT, and BIBSANIT. It is also focused on manufacturing Ready to Use Therapeutic Food (RUTF), which is used for the treatment of malnourishment among various acute malnourished children. The Company is switched over to bivalent oral polio vaccine (bOPV) from trivalent oral polio vaccine (tOPV). It is also diversified into plasma-derived medicines and Oral Cholera vaccines. The Company's manufacturing unit is located at Village Chola, Bulandshahr, Uttar Pradesh, India.

MANAGEMENT

Sanjay Mishra Managing Director, Executive Director
Sandip Lal Company Secretary

BHARAT IMMUNOLOGICA AND BIO CORP SUMMARY

Bharat Immunologica And Bio Corp is trading 4.19% upper at Rs 24.36 as compared to its last closing price. Bharat Immunologica And Bio Corp has been trading in the price range of 25.00 & 23.92. Bharat Immunologica And Bio Corp has given -1.52% in this year & 6.81% in the last 5 days.

The company posted a net profit of -4.92 Crores in its last quarter.

Listed peers of Bharat Immunologica And Bio Corp include Pharmaids Pharmaceuticals (1.62%), Welcure Drugs And Pharmaceutic (-2.31%), Bharat Immunologica And Bio Corp (4.19%) etc.

Bharat Immunologica And Bio Corp has a 59.25% promoter holding & 40.75% public holding.

FAQs about Bharat Immunologica And Bio Corp

Bharat Immunologica And Bio Corp is trading at 24.36 as on 19 May, 2025 3:44:33 PM. This is 4.19% upper as compared to its previous closing price of 23.38

The market capitalization of Bharat Immunologica And Bio Corp is 105.91 Cr as on 19 May, 2025 3:44:33 PM.

The 52 wk high for Bharat Immunologica And Bio Corp is 35.88 whereas the 52 wk low is 19.00

Bharat Immunologica And Bio Corp can be analyzed on the following key metrics -

TTM P/E: -
Sector P/E: 34.93
Dividend Yield: 0%
D/E ratio: -

Bharat Immunologica And Bio Corp reported a net profit of -17.06 Cr in 2023.

Bharat Immunologica And Bio Corp Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Bharat Immunologica And Bio Corp Share Price

Price Range

Key Metrics

Bharat Immunologica And Bio Corp Analysis

Bharat Immunologica And Bio Corp News

India readies state-run firms to manufacture Covaxin

Bharat Immunologica And Bio Corp Financials

Forecast

Forecast

Forecast

Bharat Immunologica And Bio Corp Technical

Bharat Immunologica And Bio Corp Peers

Bharat Immunologica And Bio Corp Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Bharat Immunologica And Bio Corp

MANAGEMENT

BHARAT IMMUNOLOGICA AND BIO CORP SUMMARY

FAQs about Bharat Immunologica And Bio Corp

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue